Allos Therapeutics, Inc.
11080 Circlepoint Road
Suite 200
Westminster,
CO 80020
Phone: 303-426-6262
Fax: 303-412-9160
Web Site: http://www.allos.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumulates preferentially in cancer cells and treats patients with relapsed or refractory peripheral T-cell lymphoma. The company also offers RH1, a small molecule chemotherapeutic agent, which is under Phase I trial to treat patients with advanced solid tumors and non-Hodgkins lymphoma. In addition, it is evaluating Pralatrexate in various Phases for the treatment of non-Hodgkin's Lymphoma and Hodgkin's disease, cutaneous T-cell lymphoma, non-small cell lung cancer, bladder cancer, and other solid tumor indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Mr. Paul L. Berns , 43
Chief Exec. Officer, Pres and Exec. Director |
$
795.00K | N/A | Mr. David C. Clark , 41
Chief Financial Officer, Principal Accounting Officer, VP of Fin., Treasurer and Assistant Sec. |
$
259.00K | N/A | Mr. Marc H. Graboyes , 40
Sr. VP, Sec. and Gen. Counsel |
$
385.00K | N/A | Mr. James V. Caruso , 51
Chief Commercial Officer and Exec. VP |
$
564.00K | N/A | Mr. Bruce K. Bennett Jr., 58
VP of Pharmaceutical Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Help
0.07 (1.02%) 
Profile
Reuters offers more in-depth
